Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.

Gynecologic oncology·2026

Same author

Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer.

Nature immunology·2026

Same author

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.

Nature communications·2026

Same author

What does the future hold for antibody-drug conjugate therapies in ovarian cancer?

Expert opinion on biological therapy·2026

Same author

Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same author

Cell Culture Substrate Variation Alters Extracellular Vesicle Biogenesis Without Affecting Non-Coding Repeat RNA Profile.

Small (Weinheim an der Bergstrasse, Germany)·2026

Search research articles

Related Experiment Video

Updated: May 21, 2025

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Ovarian Cancer Therapy.

Diana Miao¹, Ursula A Matulonis¹, Rebecca L Porter²

¹Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

Cold Spring Harbor Perspectives in Medicine

|May 19, 2025

Summary

Advances in epithelial ovarian cancer (EOC) research have led to new treatments like bevacizumab and antibody-drug conjugates (ADCs). Current focus is on novel therapies and combinations for improved patient outcomes in high-grade serous ovarian cancer.

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

Related Experiment Videos

Last Updated: May 21, 2025

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

Area of Science:

Oncology
Molecular Biology
Translational Research

Background:

Epithelial ovarian cancer (EOC) research has advanced understanding of molecular alterations.
This knowledge fuels clinical trials for novel agents in newly diagnosed and recurrent EOC.
Recent approvals include bevacizumab, PARP inhibitors, and mirvetuximab soravtansine.

Purpose of the Study:

To review recent advances in epithelial ovarian cancer management.
To focus on high-grade serous ovarian cancer, the most common EOC subtype.
To briefly discuss management of rarer EOC histologic subtypes.

Main Methods:

Literature review of basic and translational research in EOC.
Analysis of clinical trials incorporating novel agents.
Discussion of recent regulatory approvals and emerging therapies.

Main Results:

Novel agents like bevacizumab, PARP inhibitors, and ADCs have gained approval.
Immune checkpoint inhibitors show limited efficacy in EOC, except in MSI-high cases.
New research explores ADCs, targeted therapies, and combination strategies.

Conclusions:

Significant progress in understanding EOC molecular landscape drives new therapeutic strategies.
Combination therapies and novel agents like ADCs show promise for improving outcomes.
Continued research into targeted and immune-based therapies is crucial for advancing EOC treatment.